

Al-ola Abdallah

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9600870/publications.pdf>

Version: 2024-02-01

21
papers

645
citations

1478505

6
h-index

996975

15
g-index

21
all docs

21
docs citations

21
times ranked

818
citing authors

#	ARTICLE	IF	CITATIONS
1	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 207-221.	10.7	544
2	Car-T Treatment for Hematological Malignancies. <i>Journal of Investigative Medicine</i> , 2020, 68, 956-964.	1.6	20
3	Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data. <i>Blood</i> , 2020, 136, 35-36.	1.4	14
4	Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial. <i>Blood</i> , 2021, 138, 162-162.	1.4	9
5	Outcomes of VD-PACE With Immunomodulatory Agent as a Salvage Therapy for Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e220-e226.	0.4	8
6	Belantamab in Combination with Dexamethasone in Patients with Triple-Class Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 1642-1642.	1.4	8
7	Health Care Reimbursement, Service Utilization, and Outcomes among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 805-813.	2.0	7
8	Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM). <i>European Journal of Haematology</i> , 2021, 107, 602-608.	2.2	7
9	SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001). <i>Blood</i> , 2021, 138, 2740-2740.	1.4	5
10	Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Hematological Malignancies: Insights from the National Inpatient Sample. <i>Blood</i> , 2020, 136, 53-54.	1.4	5
11	Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e212-e219.	0.4	3
12	Daratumumab, Pomalidomide, and Dexamethasone (DPd) for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Institution Experience. <i>Blood</i> , 2018, 132, 5642-5642.	1.4	3
13	Morphologic, immunophenotypic, and molecular genetic comparison study in patients with clonal cytopenia of undetermined significance, myelodysplastic syndrome, and acute myeloid leukemia with myelodysplasia-related changes: A single institution experience. <i>International Journal of Laboratory Hematology</i> , 2022, ...	1.3	3
14	Image Diagnosis: Splenic Infarction Associated with Oral Contraceptive Pills in a Healthy Young Woman. , 2017, 21, 16-071.		2
15	Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease. <i>EJHaem</i> , 0, , .	1.0	2
16	Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials. <i>Leukemia Research</i> , 2021, 110, 106714.	0.8	2
17	Neutralizing Antibody Responses Against Sars-Cov-2 in Patients with Plasma Cell Disorders Who Are on Active Treatment after Two Doses of mRNA Vaccination. <i>Blood</i> , 2021, 138, 3804-3804.	1.4	2
18	Health Care Reimbursement and Service Utilization Among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings. <i>Blood</i> , 2018, 132, 832-832.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Palliative Care Utilization, Transfusion Burden and Symptoms for Patients with Multiple Myeloma at the End of Life. <i>Blood</i> , 2021, 138, 4103-4103.	1.4	0
20	Hospitalization at the End of Life in Myeloma Patients: Lessons from the National Inpatient Sample. <i>Blood</i> , 2020, 136, 4-5.	1.4	0
21	A Systematic Review and Network Meta-Analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 10-12.	1.4	0